Cargando…

LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is characterized by a genomic translocation generating a permanently active BCR-ABL oncogene with a complex pattern of atypically tyrosine-phosphorylated proteins that drive the malignant phenotype of CML. Recently, the LIM and SH3 domain protein 1 (LASP1) was identifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frietsch, Jochen J., Kastner, Carolin, Grunewald, Thomas G. P., Schweigel, Hardy, Nollau, Peter, Ziermann, Janine, Clement, Joachim H., La Rosée, Paul, Hochhaus, Andreas, Butt, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170624/ https://www.ncbi.nlm.nih.gov/pubmed/24913448

Ejemplares similares

Domain organization differences explain Bcr-Abl’s preference for CrkL over CrkII
por: Jankowski, Wojciech, et al.
Publicado: (2012)

Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia
por: Butt, Elke, et al.
Publicado: (2020)

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
por: Herrmann, Andreas B., et al.
Publicado: (2020)

Modeling of Molecular Interaction between Apoptin, BCR-Abl and CrkL - An Alternative Approach to Conventional Rational Drug Design
por: Panigrahi, Soumya, et al.
Publicado: (2012)

Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer
por: Frietsch, J J, et al.
Publicado: (2010)

circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation
por: Wang, Jianming, et al.
Publicado: (2022)

New Frontiers for the Cytoskeletal Protein LASP1
por: Butt, Elke, et al.
Publicado: (2018)

A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice
por: Johnson, Kara J., et al.
Publicado: (2009)

Lasp-1 Regulates Podosome Function
por: Stölting, Miriam, et al.
Publicado: (2012)

Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2
por: Schmoker, Anna M., et al.
Publicado: (2017)

An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein
por: Orth, Martin F., et al.
Publicado: (2014)

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
por: Yu, Chuanjiang, et al.
Publicado: (2020)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma
por: Grunewald, Thomas GP, et al.
Publicado: (2007)

LASP1, a Newly Identified Melanocytic Protein with a Possible Role in Melanin Release, but Not in Melanoma Progression
por: Vaman V. S., Anjana, et al.
Publicado: (2015)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
por: Berger, A, et al.
Publicado: (2014)

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
por: Morotti, Alessandro, et al.
Publicado: (2015)

LASP1 in Cellular Signaling and Gene Expression: More than Just a Cytoskeletal Regulator
por: Butt, Elke, et al.
Publicado: (2022)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Investigating lasp-2 in cell adhesion: new binding partners and roles in motility
por: Bliss, Katherine T., et al.
Publicado: (2013)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation
por: Sontakke, Pallavi, et al.
Publicado: (2016)

De Novo Linear Phosphorylation Site Motifs for BCR-ABL Kinase Revealed by Phospho-Proteomics in Yeast
por: Smolnig, Martin, et al.
Publicado: (2023)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation
por: Grunewald, T G P, et al.
Publicado: (2007)

Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
por: Gerboth, S, et al.
Publicado: (2018)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_68pfah8ontlfmmia40h34lgonm